A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-13

Study Completion Date

2024-07-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study is to learn about the safety and effects of the study medicine (PF-07054894) in healthy Japanese participants.

The study is seeking the following participants:

* Male or female Japanese participants aged 18 years or older. The participants should be healthy after going through some medical tests.
* Have a Body Mass Index (BMI) of 16 to 32 kilogram per meter squared; and a total body weight of more than 45 kilograms (100 pounds).
* Are willing and able to follow all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

In research, the participants in clinical studies are assigned by chance to separate groups that are given different treatments. Hence participants will be by chance assigned to receive either PF-07054894 or a harmless treatment that has no medical effect (placebo). Both these will be taken by mouth for 14 days. The total duration of the study is about 11 weeks, with a follow-up via telephone about 6 weeks after first treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

NCT04269538

Healthy

COMPLETED PHASE1

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

NCT05037409

Healthy

COMPLETED PHASE1

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

NCT04427917

Healthy

COMPLETED PHASE1

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

NCT02537002

Healthy

COMPLETED PHASE1

Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants

NCT04388878

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-07054894

Group Type EXPERIMENTAL

PF-07054894 or placebo

Intervention Type DRUG

multiple oral doses of PF-07054894 for 14 days

Placebo

Group Type PLACEBO_COMPARATOR

PF-07054894 or placebo

Intervention Type DRUG

multiple oral doses of PF-07054894 for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-07054894 or placebo

multiple oral doses of PF-07054894 for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and female Japanese subjects aged 18 years or older
* Body Mass Index (BMI) of 16-32 kg/m2; and a total body weight \>45 kg (100 lb)

Exclusion Criteria

* Evidence or history of clinically significant disease or medical conditions
* Positive urine drug test or history of alcohol abuse or illicit drug use.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes